Search Results for
October 26, 2023
This week’s newsletter discusses a wolf in a moderate’s clothing, opposition to healthcare revolvers, and new polling suggesting widespread support for the CFPB.
September 27, 2023 | Revolving Door Project Newsletter
Corporate greed and emaciated federal regulatory capacity means people are needlessly suffering physically, and sometimes even dying. That’s the upshot of two recent reports from the EPA’s Office of the Inspector General (OIG). These reports illustrate the concerning state of environmental regulation and enforcement in regards to water quality and refinery emissions.
September 18, 2023
RELEASE: White House Should Deepen Its New Recognition of the Environmental Salience of Its Cancer Moonshot Initiative
The White House announced late last week that the Environmental Protection Agency is launching epa.gov/cancer as part of the Biden administration’s Cancer Moonshot efforts, and will share new information about the EPA’s role in leveraging its existing authorities to “accelerate the rate of progress to prevent cancer, including phase-outs of carcinogens, regulatory actions to protect children, workers and overburdened communities, and enforcement actions to ensure pollution is curbed.”
September 01, 2023
The Revolving Door Project’s Ananya Kalahasti and Will Royce released the following statement regarding the US Chamber of Commerce’s lawsuit regarding the Inflation Reduction Act’s Medicare prescription drug negotiation program, and a financial conflict of interest regarding the judge in the Southern District of Ohio.
August 29, 2023 | The American Prospect
Who’s Running Big Pharma’s Last Stand Against Slightly Fairer Drug Pricing
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short.
July 16, 2023 | Common Dreams
Several states have attempted to implement automatic voter registration based on Medicare enrollment—but the Centers for Medicare and Medicaid Services is still stalling.
June 23, 2023 | The American Prospect
Mark Rohrbaugh, a mid-level staffer at the National Institutes of Health, has consistently blocked the use of march-in rights to seize patents on high-cost drugs.
March 01, 2023 | Revolving Door Project Newsletter
What Makes a Good Executive Branch Official?
If we had to make one overarching argument about what makes a good executive branch official, whether at a massive cabinet-level department, a medium-sized agency, or a tiny commission, it is this: a habit of skepticism about corporate claims.
February 08, 2023 | Revolving Door Project Newsletter
Will the White House Let Covid Vaccine Prices Skyrocket?
Since the early days of the pandemic, the federal government has been pre-purchasing Covid vaccines at an average cost of around $20 per dose (around $29 per dose for the bivalent boosters) to ensure public access to vaccination at no cost. However, with Congress no longer willing to fund Covid treatment, the Biden administration has indicated that it intends to end the Covid public health emergency in May, and more or less hand over control of Covid prevention to the healthcare industry.
February 01, 2023 | Talking Points Memo
But succeeding at his Cancer Moonshot’s goals will require more than funding research into cancer treatments. As the first day of February marks the beginning of National Cancer Prevention Month, it’s worth acknowledging that cancer prevention requires different approaches than treatment, and must include a reckoning with the carcinogens that pervade our environment. If Biden really wants to fight cancer in America, he’s going to have to challenge the fossil fuel and petrochemical industries. Among other things, this means confronting an Achilles heel of the Democratic Party: domestic fracking.
January 25, 2023 | Revolving Door Project Newsletter
Biden’s Choice of Chief of Staff Threatens Populist Potential
Last Friday marked the exact midway point of Biden’s presidential term. With this newly divided Congress, there are scant possibilities for legislation in the next two years. By and large, this next stage of Biden’s presidency should be all about the executive branch: implementing recent laws, enforcing existing laws, and enacting much-needed regulation. (Biden should have been overseeing these things all along, of course—that’s what the Presidency is for!)